Previous close | 1.1600 |
Open | 1.1500 |
Bid | 0.0000 x 1000 |
Ask | 0.0000 x 4000 |
Day's range | 1.1500 - 1.2075 |
52-week range | 1.0000 - 2.0000 |
Volume | |
Avg. volume | 36,854 |
Market cap | 13.84M |
Beta (5Y monthly) | 0.70 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8000 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.50 |
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies.